Table 3.
Enriched function | p Value |
---|---|
Malar rash | |
Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent | 3.66E-18 |
Antigen processing and presentation of exogenous peptide antigen via MHC class I | 3.66E-18 |
Antigen processing and presentation of peptide antigen via MHC class I | 2.65E-17 |
Peptide antigen binding | 1.87E-15 |
Antigen processing and presentation of exogenous peptide antigen | 1.91E-14 |
Discoid rash | |
Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent | 3.67E-13 |
Antigen processing and presentation of exogenous peptide antigen via MHC class I | 3.67E-13 |
Antigen processing and presentation of peptide antigen via MHC class I | 1.73E-12 |
Peptide antigen binding | 2.57E-12 |
Antigen processing and presentation | 1.07E-10 |
No cutaneous involvement | |
Protein trimerisation | 1.60E-03 |
Type I interferon signalling pathway | 5.85E-02 |
Cellular response to type I interferon | 5.85E-02 |
Response to type I interferon | 5.85E-02 |
Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent | 5.85E-02 |
For each SLE manifestation group, results are shown for the five most significantly enriched functions. All network analyses were performed using GeneMANIA software.
DMR, differentially methylated regions; MHC, major histocompatibility.